Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.
Trelagliptin, an oral DPP-4 inhibitor, which is administered once per week and characterized by a long half-life in blood. The effects of trelagliptin on vascular endothelial functions have not been clarified to date. The objective of the present study was to examine the effects of trelagliptin on vascular endothelial functions in patients with type 2 diabetes mellitus (DM) using flow-mediated dilatation (FMD), adiponectin, and asymmetric dimethylarginine (ADMA) as evaluation indicators.



This study was a preliminary single-arm prospective pilot study. The subjects of this study were type 2 DM patients aged 20-74 years, who visited our outpatient department. The patients were treated with trelagliptin, and their FMD, adiponectin, and ADMA levels were measured at baseline and at 12 weeks after initial treatment to determine the changes during the study period.



A total of 27 patients, excluding three dropouts, were included in the population for analysis. Trelagliptin treatment showed no significant changes in FMD (2.42 ± 2.7% at baseline vs. 2.66 ± 3.8% post-treatment, P = 0.785) and ADMA (0.41 ± 0.0 µg/mL at baseline vs. 0.40 ± 0.0 µg/mL post-treatment, P = 0.402). Trelagliptin treatment resulted in a significant increase of serum adiponectin level (7.72 ± 6.9 µg/mL at baseline vs. 8.82 ± 8.3 µg/mL post-treatment, P < 0.002).



In this pilot study, trelagliptin treatment showed no significant changes in FMD. On the other hand, it was believed that trelagliptin treatment may increase serum adiponectin level. Trial Registration http://www.umin.ac.jp (Trial ID UMIN000018311).
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan. bboy98762006@yahoo.co.jp.
Satoshi
S
Ida
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Kazuya
K
Murata
Department of Clinical Laboratory, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Katunori
K
Betou
Department of Clinical Laboratory, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Chiaki
C
Kobayashi
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Yuki
Y
Ishihara
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Kanako
K
Imataka
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Akihiro
A
Uchida
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Kou
K
Monguchi
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Ryutaro
R
Kaneko
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Ryoko
R
Fujiwara
Department of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-2 Funae, 1-Chome, Ise-shi, Mie, 516-8512, Japan.
Hiroka
H
Takahashi
D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D014498:Uracil / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014664:Vasodilation / Q000187:drug effects*
D052242:Adiponectin; D001120:Arginine; D015415:Biomarkers; D001786:Blood Glucose; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D006442:Glycated Hemoglobin; D014498:Uracil; C499918:ADIPOQ protein, human; C517652:hemoglobin A1c protein, human; C018524:N,N-dimethylarginine; C042807:DPP4 protein, human; C000595449:trelagliptin
Dipeptidyl peptidase-4 inhibitor; Trelagliptin; Type 2 diabetes mellitus; Vascular endothelial functions